Evgen Pharma PLC Expands Pipeline with Novel Compounds (5309G)
23 Novembre 2015 - 8:00AM
UK Regulatory
TIDMEVG
RNS Number : 5309G
Evgen Pharma PLC
23 November 2015
For immediate release 23 November 2015
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Expands Pipeline with Novel Compounds
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, has acquired exclusive worldwide licensing rights to a
wide range of novel compounds from the Spanish National Research
Council (CSIC) and the University of Seville, Spain.
This in-licensing agreement further bolsters the intellectual
property position of the Company with rights to more than 60 new
chemical entities based on the core structure of sulforaphane, the
active ingredient in the Company's lead product SFX-01. Evgen
Pharma will use its Sulforadex(R) platform to synthesise and
stabilise the newly acquired compounds with a view to taking the
most promising into clinical development.
Under the terms of the worldwide licensing agreement, Evgen
Pharma will pay a modest upfront payment and one-off milestone
payments as the first compound progresses through clinical
development. Royalties on future sales of any marketed products
will not exceed 1% of net sales.
Patent protection for the newly in-licensed compounds is pending
in Europe, United States, China, Japan, Australia, Canada and is
granted in their national home territory of Spain.
The new compounds will complement Evgen Pharma's SFX-01, a
synthetic and stabilised version of sulforaphane, a naturally
occurring molecule with established anti-cancer and neuroprotectant
properties. Early next year, SFX-01 is expected to enter Phase II
trials in subarachnoid haemorrhage and, a few months later, in
metastatic breast cancer.
Dr Stephen Franklin, Evgen Pharma's CEO, commented: "We are
delighted to acquire the exclusive worldwide licensing rights to
these novel compounds. The University of Seville has conducted an
innovative medicinal chemistry programme based on sulforaphane and,
like sulforaphane, these novel compounds have a requirement for our
patented stabilisation technology. These new compounds give us the
opportunity to lead the intellectual property space around
sulforaphane and to build a drug development pipeline targeting
several therapeutic markets within neurology and oncology."
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466
Dr Stephen Franklin, CEO 5000
www.evgen.com
Buchanan +44 (0) 20 7466
Mark Court, Sophie Cowles, Stephanie Watson 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney, Margarita Mitropoulou
(Corporate Finance) +44 (0) 20 7382
John Howes, Mark Treharne (Corporate Broking) 1100
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. It is also carrying out preclinical work in
multiple sclerosis and has a clinical interest in prostate cancer.
The Company's core technology is Sulforadex(R), a method for
synthesising and stabilising the naturally occurring compound
sulforaphane and novel proprietary analogues based on sulforaphane.
The lead product, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and is based
in Liverpool, UK, at the Liverpool Science Park. It joined the AIM
market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG. For further information please visit
www.evgen.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFEUFWSFISEDF
(END) Dow Jones Newswires
November 23, 2015 02:00 ET (07:00 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024